NCT02324569View on ClinicalTrials.gov

A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

December 27, 2014

Primary Completion Date

December 28, 2016

Study Completion Date

December 28, 2016

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

SYR-472

SYR-472 tablets

DRUG

Placebo

Placebo tablets

Trial Locations (65)

Unknown

Nagoya

Hirosaki

Kurume

Sapporo

Koga

Mito

Naka

Tsuchiura

Ushiku

Kanazawa

Satsumakawauchi

Chigasaki

Fujisawa

Sendai

Hirakata

Kashihara

Suita

Ageo

Sangou

Hamamatsu

Shimada

Koyama

Shimono

Chiyoda-ku

Nerima-ku

Shinjuku-ku

Suginami-ku

Tama

Shimonoseki

Shunann

Ageo

Aomori

Chiba

Chigasaki

Chiyoda-ku

Fujisawa

Fukuoka

Hamamatsu

Hirakata

Hirosaki

Kagoshima

Kanazawa

Kashiwara

Koga

Koyama

Kumamoto

Kurume

Kyoto

Mito

Nagoya

Naka

Nerima-ku

Osaka

Sangō

Satsumakawauchi

Sendai

Shimada

Shimono

Shimonoseki

Shinjuku-ku

Shizuoka

Suginami-ku

Tama

Toyama

Tsuchiura

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY